8-K: Humana Reports Strong Q1 2026 Results, Affirms Guidance

Humana Inc. announced first quarter 2026 financial results, with Adjusted EPS at the high end of guidance, and affirmed its full-year 2026 adjusted financial outlook.

Summary

• Humana reported first quarter 2026 (1Q26) results with GAAP diluted earnings per share (EPS) of $9.83 and Adjusted EPS of $10.31, which was at the high end of the company's guidance range.
• The Insurance segment reported a GAAP benefit ratio of 89.4%, slightly favorable to guidance, and the company affirmed its full-year 2026 Insurance segment benefit ratio guidance.
• Full-year 2026 GAAP EPS guidance was revised to 'at least $8.36' from 'at least $8.89', while Adjusted EPS guidance was affirmed at 'at least $9.00'.
• The company affirmed its full-year 2026 individual Medicare Advantage (MA) membership growth expectation of approximately 25%.
• CenterWell Senior Primary Care saw sequential growth of 110,500 patients, over 22%, including acquisitions.
• CenterWell Pharmacy and Cost Plus are partnering on new employer prescription drug solutions.
• State-based contracts membership grew by approximately 50,000 in 1Q26.
• George Renaudin, Insurance Segment President, will retire effective June 29, 2026, with Aaron Martin set to assume the role.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with strong execution in the first quarter meeting or exceeding expectations, and affirmation of full-year guidance, despite a downward revision in GAAP EPS and acknowledgment of headwinds.

Positives

• 1Q26 Adjusted EPS of $10.31 met the high end of the company's guidance (110%-115% of FY2026 Adjusted EPS).
• Insurance segment benefit ratio of 89.4% was slightly favorable to guidance ('just under 90%').
• Medical and pharmacy cost trends are reported as slightly better than expectations.
• CenterWell segment showed solid growth across all business lines.
• Consolidated operating cost ratio improved year-over-year to 10.0% (adjusted), and the Insurance segment operating cost ratio improved to 7.3% (adjusted).
• Individual Medicare Advantage membership growth is affirmed at approximately 25% for FY2026.
• CenterWell Senior Primary Care patient growth exceeded 22% sequentially.
• The company affirmed its full-year 2026 Adjusted EPS guidance of 'at least $9.00'.

Negatives

• GAAP EPS guidance for FY2026 was revised downwards to 'at least $8.36' from 'at least $8.89'.
• The company anticipates a year-over-year decline in FY2026 Adjusted EPS due to the Star Ratings headwind for Bonus Year (BY) 2026.
• The CenterWell segment experienced higher operating cost ratios due to the final year of the v28 risk model revision phase-in, acquisition integration costs, and increased volume in specialty pharmacy.
• There is a persistent gap between the Final MA Rate Notice and medical cost trend, requiring benefit adjustments.
• The number of Humana's Medicare Advantage plans rated 4-star or higher significantly declined in 2025, impacting quality bonus payments.

Risks

• Failure to properly design and price products competitively could adversely affect profitability.
• Insufficient premiums to cover healthcare costs could materially impact profitability.
• Inability to implement clinical initiatives to improve member experience and lower costs could be detrimental.
• Inadequate estimates of benefits expense could lead to adverse profitability.
• Failure to effectively implement operational and strategic initiatives, including Medicare, CenterWell, and integrated care models, could negatively impact the business.
• The decline in Star Ratings negatively impacts 2026 quality bonus payments and may affect revenues, operating results, and cash flows.
• Cybersecurity threats and data security incidents could materially affect the business.
• Involvement in various legal actions and governmental investigations could result in substantial monetary damages or changes in business practices.

Future Outlook

Humana affirmed its full-year 2026 Adjusted EPS guidance of 'at least $9.00' and revised its GAAP EPS guidance to 'at least $8.36'. The company expects a year-over-year decline in Adjusted EPS due to the Star Ratings headwind. Full-year revenue is projected to be at least $160 billion. Medicare Advantage membership growth is expected to be approximately 25%. The company anticipates second quarter earnings to be 80%-85% of expected full-year Adjusted earnings.

Management Comments

• "We've had a solid start to the year and feel good about how our operating execution and transformation initiatives are setting us up for the future," said Humana President and CEO Jim Rechtin.
• "We continue to make progress where it counts for customers - quality experience and outstanding care."
• "Pleased with a solid start to 2026, reporting 1Q26 Adjusted Earnings Per Share (EPS) of $10.31, at the high end of our guidance range."
• "While it remains early, available information to date suggests that medical and pharmacy cost trends are slightly better than our expectations, across both new and existing membership."
• "All in, we believe our expanded membership base, relentless focus on returning to Top Quartile Stars results, and continued pricing discipline position us well to deliver a stable and compelling MA margin and unlock the earnings potential of the business by 2028 as laid out at our 2025 Investor Day."

Industry Context

StockSavvy.ai notes that Humana's results reflect ongoing trends in the U.S. healthcare insurance market, particularly within Medicare Advantage. The company's focus on CenterWell for integrated care services and pharmacy solutions aligns with broader industry efforts to manage costs and improve patient outcomes. The mention of the Inflation Reduction Act (IRA) impacting Part D direct subsidies highlights the influence of recent legislation on the sector.

Comparison to Industry Standards

• Humana's 1Q26 Adjusted EPS of $10.31 is at the high end of its guidance, indicating strong performance relative to its own expectations.
• The Insurance segment benefit ratio of 89.4% is slightly favorable to guidance, suggesting better-than-expected cost management within its core insurance operations.
• The company's affirmed FY2026 Adjusted EPS guidance of 'at least $9.00' provides a benchmark for future performance expectations within the health insurance sector.
• The Medicare Advantage membership growth target of approximately 25% for FY2026 indicates an aggressive growth strategy compared to many competitors in the managed care space.
• The CenterWell Senior Primary Care patient growth of over 22% sequentially demonstrates significant expansion in its care delivery segment, potentially outpacing growth in similar service lines at other diversified health companies.

Management Changes

Legal Proceedings

• Humana filed a lawsuit seeking to set aside and vacate the 2025 Star Ratings of its Medicare Advantage plans, which was rejected by the Court on October 14, 2025, and the company has appealed.
• Humana is involved in various legal actions, including provider contract disputes and qui tam litigation.
• The company is subject to governmental and internal investigations.

Stakeholder Impact

• Shareholders: Affirmation of Adjusted EPS guidance and positive Q1 results are generally favorable, though the GAAP EPS revision and Star Ratings headwind warrant attention.
• Members: Continued focus on quality experience and care, with growth in Medicare Advantage and CenterWell services.
• Employees: Management succession planning is underway for key leadership roles.
• Providers: Ongoing partnerships and value-based care models continue to be a focus.
• Regulators/Government: Subject to significant government regulation, including Medicare and Medicaid programs, and ongoing legal and regulatory scrutiny.

Next Steps

• George Renaudin will focus on the annual Medicare Advantage bid process until his retirement.
• Aaron Martin will begin leading day-to-day management of the Insurance Segment.
• John Barger will begin leading Medicare Advantage operations effective immediately.
• Humana will host a question-and-answer session for analysts on April 29, 2026, at 8:00 a.m. ET.
• A decision on the Illinois Temporary Assistance for Needy Families (TANF) RFP is anticipated in the second quarter of 2026.
• The company continues to evaluate a pipeline of initiatives to further strengthen the balance sheet.

Key Dates

Recommendation

The report shows a solid operational quarter with adjusted results meeting expectations, but the downward revision in GAAP EPS guidance and ongoing headwinds from Star Ratings and cost trends suggest a cautious approach. While growth in Medicare Advantage and CenterWell is positive, the persistent gap between rates and costs requires careful monitoring. Therefore, a 'hold' recommendation is appropriate pending further clarity on margin stabilization and the impact of strategic initiatives.

Keywords

Humana, SEC Filing, 8-K, Quarterly Results, Medicare Advantage, CenterWell, Health Insurance, Financial Results